Tag: DurAVR THV
Anteris marks first successful implantation of DurAVR THV heart valve
ASX-listed biotechnology company Anteris Technologies has announced the successful use of its DurAVR THV biomimetic valve in a valve-in-valve (ViV) procedure.
Anteris awarded utility patent for novel transcatheter heart valve replacement
Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
Don’t get left behind: Manufacturing’s urgent need for digital transformation
As digital transformation reshapes industries worldwide, manufacturers in Australia and beyond are finding themselves at the forefront of an evolution. This shift presents opportunities for companies looking to improve efficiency, drive innovation, and boost growth.
